Get started
Author

Clara Bono

Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab
2021 · Laura Bergantini, Miriana d’Alessandro, et al. · Scandinavian Journal of Immunology · 23
PDF
Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from “FOLL12” Phase III Trial of the Fondazione Italiana Linfomi
2024 · Simone Ferrero, Ilaria Del Giudice, et al. · Blood · 2
MRD Monitoring By Euroclonality IGH Based NGS Approach Predicts Outcome in Follicular Lymphoma Patients Lacking a Conventional BCL2::IGH Marker: A Substudy from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial
2023 · Elisa Genuardi, Beatrice Alessandria, et al. · Blood · 2
PDF
Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real‐Life Italian Multicenter Harmonization Experience
2026 · Stefania Oliva, Marina Martello, et al. · Cancer Medicine · 1
An Automated Cartridge-Based Microfluidic System for Real-Time Quantification of BCR::ABL1 Transcripts in Chronic Myeloid Leukemia: An Italian Experience
2025 · Alice Costanza Danzero, Enrico Marco Gottardi, et al. · International Journal of Molecular Sciences · 1
PDF
Optimizing Molecular Diagnosis of Systemic Mastocytosis in the Era of KIT Tyrosine Kinase Inhibitors: Results of a Survey and of a Nationwide Proficiency Control Round of KIT D816V Mutation Testing Promoted By the RIMA (Rete Italiana MAstocitosi) Association
2024 · Simona Soverini, Cecilia Monaldi, et al. · Blood · 1
PDF
A new digital droplet PCR method for looking at epigenetics in diffuse large B ‐cell lymphomas: The role of BMI1 , EZH2 , and USP22 genes
2024 · Alessio Lusci Gemignani, Robel Papotti, et al. · International Journal of Laboratory Hematology · 1
PDF
CLL-446: Comparative Assessment of Measurable Residual Disease Detection and Immunological Effects in Relapsed CLL Patients Treated With Rituximab-Venetoclax in the Real World: Insights From the “Dedalus” Protocol
2026 · Maria D'Amato, Claudia Baratè, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CLL-446: Comparative Assessment of Measurable Residual Disease Detection and Immunological Effects in Relapsed CLL Patients Treated With Rituximab-Venetoclax in the Real World: Insights From the “Dedalus” Protocol
2026 · Maria D'Amato, Claudia Barate, et al. · Clinical Lymphoma Myeloma & Leukemia
Correction: Danzero et al. An Automated Cartridge-Based Microfluidic System for Real-Time Quantification of BCR::ABL1 Transcripts in Chronic Myeloid Leukemia: An Italian Experience. Int. J. Mol. Sci. 2025, 26, 8932
2026 · Alice Costanza Danzero, Enrico Marco Gottardi, et al. · International Journal of Molecular Sciences
PDF
P110 | Molecular evaluation of ROCK2 and IGFBP6 dynamics following CAR-T therapy: potential biomarkers of inflammation
2026 · Clara Bono · Haematologica
PDF
P024 | Inflammatory and epigenetic mechanisms driving chronic myeloid leukemia: advances from the ‘Stem CML Cure’ project
2026 · Clara Bono · Haematologica
PDF
Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)
2024 · Riccardo Bomben, Daniela Drandi, et al. · Blood
CLL-130 Update From the Dedalo Protocol: An Integrated Approach to MRD in CLL Patients Receiving Venetoclax Plus Rituximab
2023 · Fabrizio Mavilia, Francesco Ghio, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CLL-130 Update From the Dedalo Protocol: An Integrated Approach to MRD in CLL Patients Receiving Venetoclax Plus Rituximab
2023 · Fabrizio Mavilia, Francesco Ghio, et al. · Clinical Lymphoma Myeloma & Leukemia
Pb1981: Experience of Four Laboratories of the Italian Cml Labnet Network in the Use of the Cepheid Cartridge System
2023 · Barbara Izzo, Fabrizio Quarantelli, et al. · HemaSphere
CLO23-053: Update From the Dedalo Protocol: An Integrated Approach to MRD in CLL Patients Receiving Venetoclax Plus Rituximab
2023 · Fabrizio Mavilia, Francesco Ghio, et al. · Journal of the National Comprehensive Cancer Network
CLL-045 The Dedalo Protocol: An Integrated Approach to MRD in CLL Patients Receiving Venetoclax Plus Rituximab
2022 · Fabrizio Mavilia, Francesco Ghio, et al. · Clinical Lymphoma Myeloma & Leukemia
Poster: CLL-045 The Dedalo Protocol: An Integrated Approach to MRD in CLL Patients Receiving Venetoclax Plus Rituximab
2022 · Fabrizio Mavilia, Francesco Ghio, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 23
Citation count: 31
H-index: 2
I10-index: 1
Year
Topic
Type